Evidence map›Paper›PMID 26205955›Full record

Trial reportBMC cancer2015

Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Helga Helseth Hektoen, Kjersti Flatmark, Yvonne Andersson, Svein Dueland, Kathrine Røe Redalen, Anne Hansen Ree

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00278694 (Oxaliplatin and 5-FU Based Preoperative Chemoradiation), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00278694 phase2completednot on this map

Oxaliplatin and 5-FU Based Preoperative Chemoradiation

TypeinterventionalSponsorOslo University HospitalRan2005 to 2016Enrolled109ConditionsRectal CancerArmsOxaliplatin, Chemoradiation, 5-FU, Preoperative chemoradiation, Pelvic surgery
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Cancer metabolism: New insights into classic characteristics.The Japanese dental science review · 2018
    Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Helga Helseth HektoenInstitute of Clinical Medicine, University of Oslo, P.O. Box 1171, Blindern, 0318, Oslo, Norway. helga.hektoen@medisin.uio.no.
Kjersti FlatmarkInstitute of Clinical Medicine, University of Oslo, P.O. Box 1171, Blindern, 0318, Oslo, Norway. Kjersti.Flatmark@rr-research.no.
Yvonne AnderssonDepartment of Tumour Biology, Oslo University Hospital - Norwegian Radium Hospital, P.O.Box 4950, Nydalen, 0424, Oslo, Norway. Yvonne.Andersson@rr-research.no.
Svein DuelandDepartment of Oncology, Oslo University Hospital - Norwegian Radium Hospital, P.O.Box 4950, Nydalen, 0424, Oslo, Norway. svedue@ous-hf.no.
Kathrine Røe RedalenDepartment of Oncology, Akershus University Hospital, P.O. Box 1000, 1478, Lørenskog, Norway. k.r.redalen@medisin.uio.no.
Anne Hansen ReeInstitute of Clinical Medicine, University of Oslo, P.O. Box 1171, Blindern, 0318, Oslo, Norway. a.h.ree@medisin.uio.no.
Akershus University Hospital · NOOslo University Hospital · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLocally advanced rectal cancer (LARC) comprises heterogeneous tumours with predominant hypoxic components. The hypoxia-inducible metabolic shift causes microenvironmental acidification generated by carbonic anhydrase IX (CAIX) and facilitates metastatic progression, the dominant cause of failure in LARC.

methodsUsing a commercially available immunoassay, circulating CAIX was assessed in prospectively archived serial serum samples collected during combined-modality neoadjuvant treatment of LARC patients and correlated to histologic tumour response and progression-free survival (PFS).

resultsPatients who from their individual baseline level displayed serum CAIX increase above a threshold of 224 pg/ml (with 96 % specificity and 39 % sensitivity) after completion of short-course neoadjuvant chemotherapy (NACT) prior to long-course chemoradiotherapy and definitive surgery had significantly better 5-year PFS (94 %) than patients with below-threshold post-NACT versus baseline alteration (PFS rate of 56 %; p < 0.01). This particular CAIX parameter, ΔNACT, was significantly correlated with histologic ypT0-2 and ypN0 outcome (p < 0.01) and remained an independent PFS predictor in multivariate analysis wherein it was entered as continuous variable (p = 0.04).

conclusionsOur results indicate that low ΔNACT, i.e., a weak increase in serum CAIX level following initial neoadjuvant treatment (in this case two cycles of the Nordic FLOX regimen), might be used as risk-adapted stratification to postoperative therapy or other modes of intensification of the combined-modality protocol in LARC.

trial registrationClinicalTrials.gov NCT00278694.

Indexed as

AdultAgedAntigens, NeoplasmCarbonic Anhydrase IXCarbonic AnhydrasesChemoradiotherapy, AdjuvantChemotherapy, AdjuvantFemaleHumansMaleMiddle AgedNeoadjuvant TherapyProspective StudiesRectal NeoplasmsSurvival AnalysisTreatment OutcomeAntigens, NeoplasmCA9 protein, humanCarbonic Anhydrase IXCarbonic Anhydrases

Identifiers

PMID26205955
PMCPMC4513373
OpenAlexW1672620526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.